Skip to main content

Table 4 Clearance of HPV by male circumcision status

From: Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study

HPV Type

Uncircumcised men

Circumcised men

Log-rank test p

HR (95% CI) [circumcised versus uncircumcised]

New infections/Cleared infections

Median time to clearance (months; 95% CI)

New infections/Cleared infections

Median time to clearance (months; 95% CI)

Any HPV a

2973/2392

6.6 (6.4, 6.8)

1841/1480

7.1 (6.8, 7.3)

<0.001

0.85 (0.80-0.91)

Oncogenic b

1129/937

6.5 (6.3, 6.8)

767/629

6.7 (6.4, 7.1)

<0.001

0.83 (0.75-0.92)

16

145/118

7.1 (6.3, 8.9)

113/79

11.1 (7.2, 18.4)

<0.001

0.56 (0.42-0.75)

18

71/63

6.5 (6.1, 8.1)

51/44

6.3 (6.2, 7.2)

0.84

1.04 (0.71-1.54)

31

49/39

7.2 (6.5, 14.5)

37/31

6.4 (6.1, 6.9)

0.23

1.34 (0.83-2.17)

33

16/13

6.9 (5.9, 17.6)

16/16

6 (5.8, 6.6)

0.02

2.54 (1.12-5.73)

35

34/26

11.3 (6.5, 18.1)

18/15

10.8 (7.1, N.E.)

0.86

0.95 (0.50-1.80)

39

83/66

7 (6.3, 17.3)

71/56

11.2 (7.4, 12.8)

0.68

0.93 (0.65-1.32)

45

77/65

6.3 (6.1, 10.6)

51/48

6.1 (6.1, 6.5)

0.23

1.26 (0.87-1.84)

51

144/116

6.4 (6, 7.8)

117/88

8 (6.4, 13.1)

0.02

0.72 (0.54-0.95)

52

139/119

6.4 (6, 7.6)

84/70

6.7 (6.4, 12)

0.20

0.82 (0.61-1.11)

56

58/45

6 (6, 8.9)

44/41

6.3 (6, 7.9)

0.36

1.21 (0.79-1.86)

58

72/59

6.9 (6, 11.4)

34/26

7.1 (6.2, 12.9)

0.20

0.73 (0.46-1.17)

59

122/103

6.2 (6, 6.7)

89/73

6.4 (6.2, 8.5)

0.11

0.78 (0.58-1.06)

68

119/105

6.2 (6, 6.8)

42/42

6.4 (6.2, 10.4)

0.91

0.97 (0.68-1.39)

Non-oncogenic c

1844/1455

6.7 (6.4, 6.9)

1074/851

7.2 (6.9, 7.8)

<0.001

0.86 (0.79-0.93)

6

156/142

6.1 (6, 6.4)

80/61

7.8 (6.5, 12.5)

<0.001

0.60 (0.44-0.81)

11

37/27

7.8 (6.2, 14)

19/15

6.6 (6, 18.1)

0.54

1.22 (0.65-2.31)

26

17/14

6 (5.9, 7.1)

5/5

6.1 (6, N.E.)

0.62

0.76 (0.27-2.13)

40

47/41

6.4 (6, 7.8)

34/27

6.5 (6.2, 17.6)

0.09

0.66 (0.40-1.08)

42

63/53

9.1 (6.4, 12.3)

21/18

7.8 (6.2, N.E.)

0.96

1.02 (0.59-1.75)

53

150/123

6.7 (6.3, 7.8)

88/68

7.5 (6.2, 12.5)

0.10

0.78 (0.58-1.05)

54

111/86

8.3 (6.4, 12.1)

70/56

6.9 (6.4, 13.1)

0.93

1.02 (0.72-1.42)

55

67/53

7.2 (6.2, 12)

50/37

7 (6.6, 18.2)

0.20

0.76 (0.50-1.16)

61

126/89

6.5 (6.1, 8.5)

48/43

6.9 (6.4, 13.3)

0.86

0.97 (0.67-1.40)

62

148/104

7.9 (6.5, 11.8)

94/73

7.9 (6.7, 12.3)

0.88

1.02 (0.76-1.38)

64

8/8

6 (5.9, N.E.)

2/2

5.7 (5.5, N.E.)

0.04

6.06 (0.84-43.74)

66

110/90

6.8 (6.2, 8.5)

87/69

7.1 (6.5, 11.9)

0.49

0.89 (0.65-1.23)

67

35/32

6 (6, 7.2)

19/19

6.3 (6, 7.4)

0.38

1.28 (0.71-2.31)

69

9/9

6 (5.7, N.E.)

2/2

7.1 (6.2, N.E.)

0.99

0.98 (0.20-4.93)

70

62/53

6.8 (6.2, 11.7)

32/28

6.7 (6.2, 12)

0.54

1.15 (0.73-1.83)

71

54/39

7.5 (6.2, 13)

14/9

7.5 (6, N.E.)

0.53

0.79 (0.38-1.64)

72

49/43

6.1 (6, 7.4)

25/23

6.2 (6, 7.1)

0.35

1.28 (0.76-2.17)

73

49/39

6.2 (6, 9.2)

35/30

7.6 (6.6, 13.6)

0.45

0.83 (0.51-1.33)

81

94/72

7.2 (6.4, 10.3)

39/35

6.6 (6.2, 11.5)

0.29

1.25 (0.83-1.88)

82

30/26

6.2 (6, 11.7)

25/21

6.4 (6.2, 14.2)

0.28

0.73 (0.40-1.32)

83

55/45

6.9 (6, 9.5)

32/25

8 (6.4, 13.9)

0.25

0.75 (0.46-1.22)

84

170/126

7.2 (6.4, 11.4)

131/91

10.4 (6.7, 13.8)

0.07

0.78 (0.60-1.03)

89

166/116

7.2 (6.3, 11.5)

115/88

8.4 (7.7, 12.5)

0.15

0.81 (0.62-1.07)

IS39

31/25

6.2 (6, 13.2)

7/6

13.1 (5.9, N.E.)

0.78

0.87 (0.35-2.12)

  1. aAny HPV was defined as at least one of 37 HPV genotypes;
  2. bOncogenic HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68;
  3. cNon-oncogenic HPV types: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89 (CP6108), and IS39;
  4. NOTE: Analysis of clearance was limited to incident HPV detection; NE, not estimable; HR, hazard ratio; CI, confidence interval.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us